NEW YORK, Aug. 11, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Replimune Group, Inc. ("Replimune" or the "Company")(NASDAQ: REPL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or...
Related Questions
What is the expected impact on the stock's volatility and implied volatility in options markets?
Are there any insider trades or notable positions being taken in response to the news?
How should I adjust my risk management or position sizing for REPL given this development?
What is the potential financial exposure for Replimune from the class action lawsuit?
When are the upcoming deadlines for investors to file claims?
How might the lawsuit affect Replimune's upcoming earnings guidance?
Will there be a significant increase in short interest or sell pressure on REPL?
How does this legal issue compare to recent class actions against similar biotech firms?
What is the likelihood of a settlement versus a court trial?
Could this lawsuit trigger a material adverse change (MAC) clause in any of Replimune's contracts?